250274-91-0

Basic information

• Product Name: Azetidine-2-Methanol
• Synonyms: Azetidine-2-Methanol;Azetidin-2-ylmethanol HCl
• CAS NO: 250274-91-0
• Molecular Formula: C4H9NO
• Molecular Weight: 87.12036
• Mol File: 250274-91-0.mol

Chemical Properties

• Boiling Point: 151.9±13.0 °C(Predicted)
• Appearance: /
• Density: 1.017±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: Azetidine-2-Methanol(CAS DataBase Reference)
• NIST Chemistry Reference: Azetidine-2-Methanol(250274-91-0)
• EPA Substance Registry System: Azetidine-2-Methanol(250274-91-0)

Safety Data

• Hazardous Substances Data: 250274-91-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Azetidine-2-Methanol is used as a chiral building block for the synthesis of various pharmaceuticals and fine chemicals. Its unique structure and properties make it a valuable intermediate in the development of new drugs and therapeutic agents.
Used in Organic Synthesis:
Azetidine-2-Methanol is used as a precursor in organic synthesis, enabling the creation of complex molecules and compounds with potential applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Chemical Production:
Azetidine-2-Methanol serves as an important intermediate in the chemical production process, contributing to the synthesis of a wide range of products with diverse applications in various sectors.

Upstream product

• 162698-26-2 azetidine-2-carboxylic acid methyl ester hydrochloride 
• 2133-34-8 (2S)-azetidine-2-carboxylic acid 
• 95729-87-6 benzyl (2R)-4-oxoazetidine-2-carboxylate 
• 69684-69-1 (S)-Azetidin-2-carbonsaeuremethylester-hydrochlorid 
• 766483-76-5 azetidine-2-carboxylic acid ethyl ester 
• 503-29-7 azetidine 
• 50-00-0 formaldehyd 

Downstream Products

• 161511-85-9 2-(S)-hydroxymethyl-azetidine-1-carboxylic acid tert-butyl ester 
• 161511-90-6 (R)-1-t-butyloxycarbonyl-2-azetidinemethanol 

Relevant articles and documents

TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

Synthesis and biological evaluation of Tc-99m-cyclopentadienyltricarbonyl-technetium-labeled A-85380: An imaging probe for single-photon emission computed tomography investigation of nicotinic acetylcholine receptors in the brain

We have designed (S)-(5-(azetidin-2-ylmethoxy)pyridine-3-yl)methyl cyclopentadienyltricarbonyl technetium carboxylate ([99mTc]CPTT–A–E)with high affinity for nicotinic acetylcholine receptors (nAChRs)using (2(S)-azetidinylmethoxy)-pyridine (A-85380)as the lead compound to develop a Tc-99m-cyclopentadienyltricarbonyl-technetium (99mTc)-labeled nAChR imaging probe. Because technetium does not contain a stable isotope, cyclopentadienyltricarbonyl rhenium (CPTR)was synthesized by coordinating rhenium, which is a homologous element having the same coordination structure as technetium. Further, the binding affinity to nAChR was evaluated. CPTR–A–E exhibited a high binding affinity to nAChR (Ki = 0.55 nM). Through the radiosynthesis of [99mTc]CPTT–A–E, an objective compound could be obtained with a radiochemical yield of 33% and a radiochemical purity of greater than 97%. In vitro autoradiographic study of the brain exhibited that the local nAChR density strongly correlated with the amount of [99mTc]CPTT–A–E that was accumulated in each region of interest. Further, the in vivo evaluation of biodistribution revealed a higher accumulation of [99mTc]CPTT–A–E in the thalamus (characterized by the high nAChR density)when compared with that in the cerebellum (characterized by the low nAChR density). Although additional studies will be necessary to improve the uptake of [99mTc]CPTT–A–E to the brain, [99mTc]CPTT–A–E met the basic requirements for nAChR imaging.

Development of 99mTc radiolabeled A85380 derivatives targeting cerebral nicotinic acetylcholine receptor: Novel radiopharmaceutical ligand 99mTc-A-YN-IDA-C4

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels that have been implicated in higher brain functions. To elucidate the functional mechanisms underlying nAChRs and contribute significantly to development of drugs targeting neurological and neuropsychiatric diseases, non-invasive nuclear medical imaging can be used for evaluation. In addition, technetium-99m (99mTc) is a versatile radionuclide used clinically as a tracer in single-photon emission computed tomography. Because A85380 is known as a potent α4β2-nAChR agonist, we prepared A85380 derivatives labeled with 99mTc using a bifunctional chelate system. A computational scientific approach was used to design the probe efficiently. We used non-radioactive rhenium (Re) for a 99mTc analog and found that one of the derivatives, Re-A-YN-IDA-C4, exhibited high binding affinity at α4β2-nAChR in both the docking simulation (?19.3 kcal/mol) and binding assay (Ki = 0.4 ± 0.04 nM). Further, 99mTc-A-YN-IDA-C4 was synthesized using microwaves, and its properties were examined. Consequently, we found that 99mTc-A-YN-IDA-C4, with a structure optimized by using computational chemistry techniques, maintained affinity and selectivity for nAChR in vitro and possessed efficient characteristics as a nuclear medicine molecular imaging probe, demonstrated usefulness of computational scientific approach for molecular improvement strategy.

CARBONITRILE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention relates to a compound of Formula 1, 2 or 3: I II III wherein A is N or -CR0--, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is -CRe --, or, -N--, where Re is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1C6 linear or branched chain alkyl, etc.;. R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1 -C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1- C6 linear or branched chain alkyl, etc.; Q is --CO--, --(CH2)q--, --(CHRs)q--, or -(CRsRt)q- -, where Rs and Rt are independently C1-C6 linear or branched chain alkyl, aryl, alkylaryl, heteroaryl or alkylheteroaryl; where q is 0, 1, 2, or 3; and, where n is 0, 1, 2, 3, 4 or 5; or, a pharmaceutically acceptable salt thereof, for the treatment of certain diseases, particularly those affected or mediated by the androgen receptor; to compbinations comprising such compounds with a second pharmaceutically active ingredient; to compositions containing such combinations; and to such combinations for the treatment of various diseases, particularly, those affected or mediated by the androgen receptor.

AURORA KINASE COMPOUNDS AND METHODS OF THEIR USE

Provided herein are pyrrolotriazine compounds for treatment of Aurora kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Processes for producing azetidine-2-carboxylic acid and intermediates thereof

PCT No. PCT/JP98/01895 Sec. 371 Date Dec. 30, 1999 Sec. 102(e) Date Dec. 30, 1999 PCT Filed Apr. 24, 1998 PCT Pub. No. WO98/47867 PCT Pub. Date Oct. 29, 1998The present invention has its object to provide a process for producing azetidine-2-carboxylic acid and an intermediate thereof, which is efficient and economical and suited for industrial practice. The present invention is related to a process for producing azetidine-2-carboxylic acid of the following formula (5), which comprises subjecting a 4-oxo-2-azetidinecarboxylic acid derivative represented by the general formula (1) to hydride reduction to give azetidine-2-methanol of the following formula (2), treating the same with an amino-protecting agent to give N-protected azetidine-2-methanol represented by the following general formula (3), treating this with an oxidizing agent to give N-protected azetidine-2-carboxylic acid represented by the following general formula (4) and, further, subjecting the amino-protecting group thereof to elimination.

Efficient asymmetric synthesis of ABT-594; a potent, orally effective analgesic

A concise asymmetric synthesis of (R)-2-chloro-5-(2- azetidinylmethoxy)pyridine (ABT-594) is presented in which the key intermediate t-butoxycarbonyl protected (2R)-azetidinylalcohol is obtained in three steps from the dibenzyl ester of D-aspartic acid in 44% yield and >99% ee.

Enantioselective hydrogenation of functionalized ketones. Synthesis and application of new chiral aminophosphine-phosphinite ligands

The chiral new aminophosphine-phosphinites (AMPP's 1-7) have been synthesised and applied successfully in the enantioselective hydrogenation of dihydro-4,4-dimethyl-2,3-furandione 8, N-benzylbenzoylformamide 9, and ethylpyruvate 10 providing the hydroxy products in up to 97, 95, and 80% ee, respectively.

Tricyclic pyridine derivatives and pharmaceutical compositions

Compounds of the formula STR1 or a pharmaceutically acceptable acid addition salt of a compound of formula I which has one or more basic substituents, are described. The compounds of formula I possess pronounced muscle relaxant, sedative-hypnotic, anticonvulsive and anxiolytic properties and have low toxicity.